RxDoctor Payments Data

Marie Zambelli, NP

Family · Sarasota, FLNPI 1508419656

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Relievant Medsystems, Inc. accounts for 63.3% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2022 at $35,075 and has fallen 95.5% since, to $1,567 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,858in general payments, 2019–2025

Across 475 payments — averaging $136.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$41K
  • Vertos Medical, Inc.$11K
  • AbbVie$3K
  • Spinal Simplicity, LLC$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Amgen$981
  • plus $5K from 42 others

What the payments were for

  • Consulting fees$13,11520%
  • Speaking & faculty fees$27,25642%
  • Travel & lodging$9,69815%
  • Food & beverage$14,72923%
  • Education$600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,858 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$28,784
Medicare patients
242
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept15$121,295
QuliptaAtogepant11$20,036
Leflunomide331$17,948
Hydroxychloroquine Sulfate446$10,788
MethotrexateMethotrexate Sodium165$2,787
Mycophenolate Mofetil25$2,411
Prednisone372$2,360
Celecoxib89$2,060
Sulfasalazine75$2,025
Gabapentin109$1,791
Minocycline Hcl22$975
Duloxetine Hcl80$892
Azathioprine41$749
Folic Acid84$587
Diclofenac Sodium37$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$3,177$20,03611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →